Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Stellar Pharmaceuticals has received patent from the Chinese Patent Office and the US Patent and Trademark Office (USPTO) for one of its lead products Uracyst (a sterile sodium chondroitin sulfate solution, 2%).
Subscribe to our email newsletter
The Chinese Letters Patent No 1758920 covers pharmaceutical compositions that comprise the greater and superior dosage size of chondroitin sulfate, and the use of those compositions for the treatment of IC/PBS.
Whereas, the US Patent No 7772210, entitled ‘Cystitis Treatment with High Dose Chondroitin Sulfate,’ describes the treatment of IC/PBS by instillation of an optimised dose of chondroitin sulfate.
Peter Riehl, president and CEO of Stellar Pharma, said: “As awareness and acceptance of Uracyst as the preferred treatment for IC/PBS continues to grow amongst physicians and patients in global markets, it is important this opportunity is well protected.
“With patents already issued in Canada, the US (a low dose patent) and Australia, and with numerous additional international patents pending, these two additional patents expand Stellar Pharma’s already formidable intellectual property estate.”